Syneron Bio raised a $150 million Series B round to advance peptide programs built for improved drug-like properties, adding to its prior year fundraising efforts that totaled $100 million. The company said the proceeds will support development of a peptide drug class drawing attention for its potential to borrow aspects of biologic performance. The funding reinforces investor appetite for next-generation peptide therapeutics, especially platforms aimed at overcoming common constraints such as stability, delivery, and exposure. For pipeline stakeholders, the raise may accelerate early translational work and move candidates toward clinical study readiness. While specific lead assets and trial timelines were not detailed in the excerpt, the size of the round suggests Syneron intends to build momentum quickly across multiple candidates or supporting platform development.